Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31348148 | 0.82 | HPGD (0.36) | GAAHPGDSMN1; SMN2ALDH1A1F2 | |
| SCHEMBL22445778 | 0.80 | TBXAS1 (0.39) | GAAHPGDSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL22445819 | 0.79 | PDK1 (0.48) | GAAALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL1417796 | 0.77 | ALDH1A1 (0.40) | GAASMN1; SMN2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL7979956 | 0.74 | CYP46A1 (0.38) | CYP46A1KDM4ERXFP1 | |
| SCHEMBL7967705 | 0.74 | CYP46A1 (0.38) | HPGDCYP46A1KDM4EMAPTRXFP1 | |
| Hydrochloric Acid SCHEMBL1417604 | 0.73 | CYP46A1 (0.37) | HPGDCYP46A1KDM4EMAPTRXFP1 | |
| SCHEMBL12424353 | 0.71 | F2 (0.37) | GAAHPGDSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL7982099 | 0.71 | CYP46A1 (0.38) | HPGDCYP46A1KDM4EMAPTRXFP1 | |
| SCHEMBL15014621 | 0.69 | HPGD (0.47) | GAAHPGDSMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | GAA 1904/4885HPGD 190/4885CYP46A1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.